

IPPS FY 2020 Final Rule - New Technologies Approved for Add-on Payments

New Technology	New Technology Description	ICD-10-PCS Codes	ICD-10-PCS Code Description	FY 2019 Maximum Add-on Payment	FY 2020 Maximum Add-on Payment
KYMRIAH® & YESCARTA®	CAR T-Cell Immune Therapy	XW033C3	Introduction of engineered autologous chimeric antigen receptor t-cell immunotherapy into peripheral vein, percutaneous approach, New Technology Group 3 OR	\$186,500	\$242,450.00
		XW043C3	Introduction of engineered autologous chimeric antigen receptor t-cell immunotherapy into central vein, percutaneous approach, New Technology Group 3		
VYXEOS™	Treatment of adults with newly diagnoses therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)	XW033B3	Introduction of cytarabine and daunorubicin liposome antineoplastic into peripheral vein, percutaneous approach, New Technology Group 3 OR	\$36,425	\$47,352.50
		XW043B3	Introduction of cytarabine and daunorubicin liposome antineoplastic into central vein, percutaneous approach, New Technology Group 3		
VABOMERE™	Treats gram-negative bacteria resistant to other current antibiotic therapies, specifically in response to urgent & growing threat of Carbapenem-resistant Enterobacteriaceae (Complicated UTIs (cUTIs))	XW033N5	Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	\$5,544	\$8,316.00
		XW043N5	Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5		
		NDC Codes: 65293-0009-01 or 70842-0120-01	NOTE: For FY2019, there were no ICD-10-PCS code(s) available for the capture of providing this medication. Instead hospitals were instructed to use one of two National Drug Codes (NDC). For FY 2020, hospitals can identify cases involving Vabomere with new ICD-10-PCS codes OR one of the NDC codes.		
Remede® System	Implantable phrenic nerve stimulator for treatment of moderate to severe central sleep apnea. Note this is placed during a minimally invasive outpatient procedure by a cardiologist.	0JH60DZ	Insertion of multiple array stimulator generator into chest subcutaneous tissue and fascia, open approach AND	\$17,250	\$22,425.00
		05H03MZ	Insertion of neurostimulator lead into right axygos vein, percutaneous approach, in combination with either, in combination with either		
		05H33MZ	Insertion of neurostimulator lead into right innominate vein, percutaneous approach OR		
		05H43MZ	Insertion of neurostimulator lead into left innominate vein, percutaneous approach		
Zemdri™	Antibiotic with enhanced activity against many multi-drug resistant (MDR) gram-negative bacteria used to treat adult patients diagnosed with cUTI and pyelonephritis	XW033G4	Introduction of Plazomicin anti-infective into peripheral vein, percutaneous approach, New Technology Group 4 OR	\$2,722.50	\$4,083.75
		XW043G4	Introduction of Plazomicin anti-infective into central vein, percutaneous approach, New Technology Group 4		
Giapreza™	First synthetic formulation of human angiotensin II used to rapidly raise blood pressure in adult patients diagnoses with septic or distributive shock	XW033H4	Introduction of synthetic human angiotensin II into peripheral vein, percutaneous approach, New Technology, Group 4 OR	\$1,500	Amount in Proposed Rule was \$1,950. Amount indicated in Final Rule is \$4,083.75. Appears to be in error.
		XW043H4	Introduction of synthetic human angiotensin II into central vein, percutaneous approach, New Technology Group 4		
Sentinel® Cerebral Protection System	This is an embolic protection (EP) device to capture and remove thrombus & debris during transcatheter aortic valve replacement (TAVR) procedures	X2A5312	Cerebral embolic filtration, dual filter in innominate artery and left common carotid artery, percutaneous approach	\$1,400	\$1,820.00
AquaBeam System (Aquablation)	Autonomous waterjet ablation therapy indicated for treatment of patients experiencing lower urinary tract symptoms caused by Benign Prostatic Hypertrophy (BPH)	XV508A4	Destruction of prostate using robotic waterjet ablation, via natural or artificial opening endoscopic, New Technology Group 4	\$1,250	\$1,625.00

IPPS FY 2020 Final Rule - New Technologies Approved for Add-on Payments

New Technology	New Technology Description	ICD-10-PCS Codes	ICD-10-PCS Code Description	FY 2019 Maximum Add-on Payment	FY 2020 Maximum Add-on Payment
ANDEXXA®	Reversal Agent for patients treated with direct and indirect Factor Xa inhibitors. Specifically in patients taking rivaroxaban (Xarelto®) or apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.	XW03372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into peripheral vein, percutaneous approach, New Technology Group 2, OR	\$14,062.50	\$18,281.25
		XW04372	Introduction of Andexanet alfa, Factor Xa inhibitor reversal agent into central vein, percutaneous approach, New Technology Group 2		
AZEDRA® (Ultrtrace® iobenguane Iodine-131) Solution	Treatment of patients diagnosed with obenguane avid malignant and/or recurrent and/or unresectable pheochromocytoma and paraganglioma	XW03355	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5, OR	N/A New for FY 2020	\$98,150.00
		XW04355	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5		
CABLIVI® (caplacizumab-yhdp)	Treatment to inhibit microclot formation in adult patients who have been diagnosed with acquired thrombotic thrombocytopenic purpura (aTTP).	XW013W5	Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 OR	N/A New for FY 2020	\$33,215.00
		XW033W5	Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 OR		
		XW043W5	Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5		
ELZONRIS™ (tagraxofusp, SL-401)	A targeted therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as blastic natural killer (NK) cell leukemia/lymphoma, administered via infusion.	XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into peripheral vein, percutaneous approach, new technology Group 5 OR	N/A New for FY 2020	\$125,448.05
		XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into central vein, percutaneous approach, new technology Group 5		
Balversa™ (Erdafitinib)	A second-line treatment of adult patients who have been diagnosed with locally advanced or metastatic urothelial carcinoma (also know as transitional cell cancer or bladder cancer) whose tumors exhibit certain fibroblast growth factor receptor (FGFR) genetic alterations as detected by an FDA-approved test, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy.	XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth, and Pharynx, External Approach, New Technology Group 5	N/A New for FY 2020	\$3,563.23
ERLEADA™ (Apalutamide)	Oral drug that is an androgen receptor inhibitor indicated for the treatment of patients who have been diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC).	XW0DXJ5	Introduction of Apalutamide Antineoplastic into Mouth and Pharnx, External Approach, New Technology Group 5	N/A New for FY 2020	\$1,858.25
SPRAVATO (Esketamine)	A nasal spray for treatment-resistant depression (TRD). As noted in the proposed rule, “patients who have not responded to at least two different anti-depressant treatments of adequate dose and duration for their current depressive episode are considered to have been diagnosed with TRD.”	3E097GC	Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening. Note: A unique ICD-10-PCS procedure to specifically identify cases involving Spravato has not yet been finalized. Therefore, cases reporting SPRAVATO will be identified with this ICD-10-PCS Procedure code for FY 2020.	N/A New for FY 2020	\$1,014.79
XOSPATA® (gilteritinib)	Indicated for the treatment of adult patients who have been diagnosed with relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.	XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	N/A New for FY 2020	\$7,312.50
JAKAFI™ (Ruxolitinib)	An oral kinase inhibitor indicated for the treatment of acute graft-versus-host disease (GVHD) in patients who have had an inadequate response to corticosteroids.	XW0DXT5	Introduction of ruxolitinib into mouth and pharynx, external approach, New Technology Group 5)	N/A New for FY 2020	\$3,977.06

IPPS FY 2020 Final Rule - New Technologies Approved for Add-on Payments

New Technology	New Technology Description	ICD-10-PCS Codes	ICD-10-PCS Code Description	FY 2019 Maximum Add-on Payment	FY 2020 Maximum Add-on Payment
<p>T2Bacteria® Panel (T2 Bacteria Test Panel)</p>	<p>According to the applicant, the T2Bacteria® Panel is indicated as an aid in the diagnosis of bacteremia, bacterial presence in the blood which is a precursor for sepsis.</p> <p>It is a multiplex diagnostic panel that detects the following five major bacterial pathogens associated with sepsis: Three gram-negative bloodstream infections: <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginos</i>, and Two Gram-positive bloodstream infection species: <i>Staphylococcus aureus</i>, and <i>Enterococcus faecium</i>.</p> <p>The applicant indicates the T2 Bacteria® Panel is the only FDA cleared diagnostic aid that has the ability to rapidly and accurately identify sepsis-causing bacteria species directly from whole blood within 3 to 5 hours, instead of the 1 to 5 days required by current standard-of-care lab blood cultures or other diagnostic technology.</p>	<p>XXE5XM5</p>	<p>Measurement of Infection, Whole Blood Nucleic Acid-base Microbial Detection, New Technology Group 5</p>	<p>N/A New for FY 2020</p>	<p>\$97.50</p>

Source: FY 2020 IPPS Final Rule in Federal Register / Vol. 84, No. 159/Friday, August 16, 2019 / Rules and Regulations - pages 42180 - 42300. Link to CMS Final Rule webpage:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page.html>